Binod Dhakal

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Jesús F. San Miguel, Binod Dhakal, Kwee Yong et al. · New England Journal of Medicine · 2023 · 615 citations · Full text

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova et al. · Journal of Clinical Oncology · 2021 · 238 citations

IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia

Anand Padmanabhan, Curtis G. Jones, Shannon M. Pechauer et al. · CHEST Journal · 2017 · 137 citations · Full text

Thrombopoiesis, Thrombosis, Blood Platelet +3

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy

Binod Dhakal, Sameem Abedin, Timothy S. Fenske et al. · Blood · 2021 · 130 citations · Full text

Vaccination, Transplantation, Vaccine Development +10